NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two
“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

In Brief

ARPA-H launches SURPASS program to accelerate clinical trials

ARPA-H launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects, aimed at removing barriers that slow clinical development and help promising treatments reach patients sooner.

October 02, 2026

Vol.52 No.36

Podcast

The Galleri MCD vote: What FDA asked its advisors to ignore

In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.

September 30, 2026

Podcast The Directors

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?

September 25, 2026

Vol.52 No.35

By Claire Marie Porter and Paul Goldberg

Cancer Policy

NCI launches AI tool to help match patients to clinical trials

NCI Director Anthony Letai announced the development of TrialMatch, an AI tool that helps oncologists identify clinical trials for their patients.

September 25, 2026

Vol.52 No.35

By Sara Willa Ernst

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

YOU MAY BE INTERESTED IN

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two
“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

NCI launches AI tool to help match patients to clinical trials

Renew today!

Subscriber content

Never miss an issue!

Login

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

YOU MAY BE INTERESTED IN

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want itLucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

NCI launches AI tool to help match patients to clinical trials

Never miss an issue!

Login

With Year One metrics in hand, Letai is ready to “bring it home” in Year Two
“I hope I don’t see any more reports of NCI cutting funding, because it just is not consistent with the facts”

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish